Questionnaire

1. Approximately 45% of South Africans living with diabetes remain undiagnosed and only half of South Africans ≥15 years of age and being treated for diabetes are achieving blood sugar control (HbA1c <7.0%):

2. The STENO-2 trial demonstrated that compared with conventional therapy, an intensive multifactorial management approach in patients with T2DM conferred a significant benefit for:

3. The recommended HbA1c target for PLWD and without diabetes-related complications is:

4. The recommended BP target for PLWD and without diabetes-related complications is:

5. The recommended LDL-C target for PLWD and without diabetes-related complications is:

6. Diabetes-related complications for which annual screening is recommended include:

7. Early intervention to preserve residual β-cell function may reduce long-term metabolic risk by reducing glycaemic variability and complications associated with T1DM and hypoglycaemia.

8. GLP-1 RA therapy is preferred over SGLT-2i for adults with T2DM and:

9. Patients who report more diabetes distress are also more likely to report more:

10. PLWD who likely have a higher risk of depressive symptoms and more diabetes distress include:

11. For patients with T2DM, the risk of developing HF is increased with:

12. For patients with T2DM and ASCVD, treatments that have proven benefit for reducing cardiovascular risk, independent of glucose control, include SGLT2is but not GLP-1 RAs.

13. Ongoing management of T1DM in primary care should include regular monitoring of:

14. The risks of hypoglycaemia and weight gain and diminished HbA1c-lowering efficacy occurs when daily basal insulin doses exceed:

15. Compared with step-wise intensification of free insulin glargine and lixisenatide treatment regimens in adults with T2DM, simultaneous intensification using FRC iGlargLixi has demonstrated: